Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Grace Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 0 | 14 | +14 |
| Shares | 0 | 179.0K | +179.0K |
| Value | $0 | $356.5K | +$356.5K |
New holders (14)
Institutions that held Grace Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 43,408 | $87.0K | 0.00% |
| Citadel Advisors LLC | 36,571 | $73.0K | 0.00% |
| Virtu Financial LLC | 27,100 | $54.0K | 0.00% |
| Jane Street Group, LLC | 18,919 | $38.0K | 0.00% |
| Geode Capital Management, LLC | 18,348 | $36.0K | 0.00% |
| Morgan Stanley | 14,749 | $29.0K | 0.00% |
| Two Sigma Securities, LLC | 13,370 | $27.0K | 0.01% |
| UBS Group AG | 4,500 | $9.00K | 0.00% |
| Royal Bank of Canada | 955 | $2.00K | 0.00% |
| Bank of America Corp | 625 | $1.00K | 0.00% |
| Federation des caisses Desjardins du Quebec | 230 | $449 | 0.00% |
| Brewin Dolphin Ltd | 3 | $6 | 0.00% |
| Tower Research Capital LLC (TRC) | 192 | $0 | 0.00% |
| Sargent Bickham Lagudis LLC | 5 | $0 | 0.00% |
Sold out (0)
Institutions that held Grace Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
None.